Hoge Stephen

About Hoge Stephen

Stephen Hoge, M.D., is one of the key senior executives at Moderna, Inc., where he serves as President. According to Moderna’s public filings, he oversees the company’s research and development organization, spanning basic science through clinical development and regulatory approvals, and he also has responsibility for early commercial efforts across a number of pipeline programs. He joined Moderna in January 2013 and has served in his current role since February 2015. Before joining Moderna, Hoge spent nearly seven years at McKinsey & Company from 2005 to 2012, where he advanced through roles of increasing responsibility and ultimately became a Partner and leader in the firm’s healthcare practice. Earlier in his career, he completed a residency in medicine at New York University/Bellevue Hospital from 2004 to 2005. He earned a B.A. in neuroscience from Amherst College and an M.D. from the University of California, San Francisco. At Moderna, Hoge has played a central role in the company’s scientific and organizational growth, particularly in advancing the mRNA platform from research into clinical and regulatory execution. His responsibilities place him at the intersection of scientific strategy, program prioritization, and the translation of innovation into approved therapies. In Moderna’s public communications, he is frequently associated with platform science, therapeutic development, and the company’s longer-term pipeline strategy. His background combines medical training, healthcare consulting, and strategic leadership, making him well suited to a biotech business operating in a highly technical and rapidly evolving environment. For investors, partners, and governance observers, he is a core executive figure in Moderna’s leadership team and in the company’s ability to turn scientific innovation into scalable commercial products.